Bio-Rad Labs Inc. A Stock
Bio-Rad Labs Inc. A Stock
A very strong showing by Bio-Rad Labs Inc. A today, with an increase of €11.20 (4.180%) compared to yesterday's price.
Our community is currently high on Bio-Rad Labs Inc. A with 4 Buy predictions and 0 Sell predictions.
With a target price of 322 € there is a slightly positive potential of 15.74% for Bio-Rad Labs Inc. A compared to the current price of 278.2 €.
Our community identified positive and negative aspects for Bio-Rad Labs Inc. A stock for the coming years. 0 users see the criterium "Revenue growth" as a plus for the Bio-Rad Labs Inc. A stock. On the other hand our users think that "Revenue growth" could be a problem in the future.
Pros and Cons of Bio-Rad Labs Inc. A in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Rad Labs Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Rad Labs Inc. A | 4.180% | 5.779% | 6.102% | 27.439% | 7.871% | -26.866% | -52.034% |
| CONMED Corp. | -0.530% | 0.535% | 22.876% | -10.476% | 7.429% | -65.505% | -66.726% |
| Penumbra Inc | 0.140% | 0.575% | 0.503% | 42.067% | 5.030% | 2.868% | 22.612% |
| Glaukos Corp | 0.000% | -2.941% | 6.452% | 66.038% | 36.788% | 100.000% | 214.286% |
Comments
Bio-Rad Laboratories (BIO) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $320.00 price target on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories (NYSE:BIO) had its price target raised by analysts at Citigroup Inc. from $350.00 to $375.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank Of Canada from $387.00 to $409.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat